Loading...
Loading...
COLL| Name | Value |
|---|---|
| Revenues | 135.5M |
| Cost of Revenue | 61.7M |
| Gross Profit | 73.8M |
| Operating Expense | 38.2M |
| Operating I/L | 35.6M |
| Other Income/Expense | -17.8M |
| Interest Income | 4.0M |
| Pretax | 17.8M |
| Income Tax Expense | 4.8M |
| Net Income/Loss | 13.0M |
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. These products are designed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
